| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm … JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ... The Lancet 387 (10031), 1909-1920, 2016 | 3890 | 2016 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2242 | 2017 |
| Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy W Choi, S Porten, S Kim, D Willis, ER Plimack, J Hoffman-Censits, B Roth, ... Cancer cell 25 (2), 152-165, 2014 | 1760 | 2014 |
| Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 577 | 2020 |
| Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer ER Plimack, RL Dunbrack, TA Brennan, MD Andrake, Y Zhou, ... European urology 68 (6), 959-967, 2015 | 494 | 2015 |
| Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial J Bellmunt, M Hussain, JE Gschwend, P Albers, S Oudard, D Castellano, ... The Lancet Oncology 22 (4), 525-537, 2021 | 331 | 2021 |
| Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a … ER Plimack, JH Hoffman-Censits, R Viterbo, EJ Trabulsi, EA Ross, ... Journal of clinical oncology 32 (18), 1895-1901, 2014 | 304 | 2014 |
| Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations SK Pal, JE Rosenberg, JH Hoffman-Censits, R Berger, DI Quinn, ... Cancer discovery 8 (7), 812-821, 2018 | 265 | 2018 |
| Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer T Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, ... New England Journal of Medicine 390 (10), 875-888, 2024 | 258 | 2024 |
| Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma D Liu, ER Plimack, J Hoffman-Censits, LA Garraway, J Bellmunt, ... JAMA oncology 2 (8), 1094-1096, 2016 | 248 | 2016 |
| Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study A Necchi, RW Joseph, Y Loriot, J Hoffman-Censits, JL Perez-Gracia, ... Annals of Oncology 28 (12), 3044-3050, 2017 | 243 | 2017 |
| NCCN Guidelines® insights: bladder cancer, version 2.2022: featured updates to the NCCN guidelines TW Flaig, PE Spiess, M Abern, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 20 (8), 866-878, 2022 | 226 | 2022 |
| Role of genetic testing for inherited prostate cancer risk: Philadelphia Prostate Cancer Consensus Conference 2017 VN Giri, KE Knudsen, WK Kelly, W Abida, GL Andriole, CH Bangma, ... Journal of Clinical Oncology 36 (4), 414-424, 2018 | 217 | 2018 |
| LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+ P) vs chemotherapy (Chemo) in previously untreated … TB Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, ... Annals of Oncology 34, S1340, 2023 | 143 | 2023 |
| Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer D Liu, P Abbosh, D Keliher, B Reardon, D Miao, K Mouw, A Weiner-Taylor, ... Nature communications 8 (1), 2193, 2017 | 130 | 2017 |
| Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience LG Gomella, J Lin, J Hoffman-Censits, P Dugan, F Guiles, CD Lallas, ... Journal of oncology practice 6 (6), e5-e10, 2010 | 124 | 2010 |
| Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer J Hoffman-Censits, WK Kelly Clinical Cancer Research 19 (6), 1335-1339, 2013 | 119 | 2013 |
| Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma V Margulis, M Puligandla, EJ Trabulsi, ER Plimack, ER Kessler, SF Matin, ... The Journal of urology 203 (4), 690-698, 2020 | 112 | 2020 |
| Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline JA Coleman, PE Clark, BR Bixler, DI Buckley, SS Chang, R Chou, ... Journal of Urology 209 (6), 1071-1081, 2023 | 99 | 2023 |
| Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes JH Hoffman-Censits, KA Lombardo, V Parimi, S Kamanda, W Choi, ... Applied Immunohistochemistry & Molecular Morphology 29 (8), 619-625, 2021 | 94 | 2021 |
